多发性骨髓瘤治疗选择中心脏毒性结局的风险平衡：伊沙佐米、来那度胺和地塞米松（IRd）对比卡非佐米、来那度胺和地塞米松（KRd）的回顾性多中心评估
Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd).
作者信息
Lee Benjamin J, Sayer Michael, Naqvi Ali A, Mai Karen T, Patel Pranav M, Lee Lisa X, Ozaki Aya F
机构信息
Department of Pharmacy Chao Family Comprehensive Cancer Center University of California Irvine Health Orange California USA.
Department of Clinical Pharmacy Practice School of Pharmacy & Pharmaceutical Sciences University of California Irvine California USA.
出版信息
EJHaem. 2025 Apr 28;6(3):e70038. doi: 10.1002/jha2.70038. eCollection 2025 Jun.
Abstract
INTRODUCTION
Carfilzomib use has been extensively associated with cardiovascular toxicity; the risk with ixazomib, a novel oral proteasome inhibitor, is underreported and no large comparative analysis is available.
METHODS
We conducted a retrospective cohort study utilizing the TriNetX platform to compare toxicity outcomes among multiple myeloma patients who received lenalidomide, dexamethasone, and ixazomib (IRd) or carfilzomib (KRd).
RESULTS
After propensity-score-matching 478 patients from each cohort, the onset of new heart failure (HR 0.25; < 0.001) and arrhythmias (HR 0.57; = 0.014) at 6 months were significantly lower with IRd while overall survival at 3 years was similar ( = 0.50).
CONCLUSION
IRd is associated with a significantly lower risk of cardiac toxicities compared to KRd.
摘要
引言
卡非佐米的使用与心血管毒性广泛相关；新型口服蛋白酶体抑制剂伊沙佐米的相关风险报道较少，且尚无大型对比分析。
方法
我们利用TriNetX平台进行了一项回顾性队列研究，以比较接受来那度胺、地塞米松和伊沙佐米（IRd）或卡非佐米（KRd）的多发性骨髓瘤患者的毒性结果。
结果
在对每个队列中的478例患者进行倾向评分匹配后，IRd组在6个月时新发心力衰竭（HR 0.25；<0.001）和心律失常（HR 0.57；=0.014）的发生率显著较低，而3年总生存率相似（=0.50）。
结论
与KRd相比，IRd发生心脏毒性的风险显著更低。
相似文献
1
Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd).
EJHaem. 2025 Apr 28;6(3):e70038. doi: 10.1002/jha2.70038. eCollection 2025 Jun.
2
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28.
3
Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
Hematology. 2023 Dec;28(1):2156731. doi: 10.1080/16078454.2022.2156731.
4
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.
5
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14.
6
Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
J Manag Care Spec Pharm. 2023 Nov;29(11):1205-1218. doi: 10.18553/jmcp.2023.23031. Epub 2023 Sep 30.
7
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study.
J Hematol Oncol. 2018 Apr 4;11(1):49. doi: 10.1186/s13045-018-0583-7.
8
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
BMC Cancer. 2021 Jan 15;21(1):73. doi: 10.1186/s12885-020-07732-1.
9
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Ann Hematol. 2021 Sep;100(9):2325-2337. doi: 10.1007/s00277-021-04534-8. Epub 2021 May 10.
10
Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data.
Curr Probl Cancer. 2024 Jun;50:101078. doi: 10.1016/j.currproblcancer.2024.101078. Epub 2024 Mar 27.
本文引用的文献
1
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma.
JAMA Netw Open. 2024 Mar 4;7(3):e243854. doi: 10.1001/jamanetworkopen.2024.3854.
2
The EASEMENT study: A multicentre, observational, cross-sectional study to evaluate patient preferences, treatment satisfaction, quality of life, and healthcare resource use in patients with multiple myeloma receiving injectable-containing or fully oral therapies.
Eur J Haematol. 2024 Jun;112(6):889-899. doi: 10.1111/ejh.14180. Epub 2024 Feb 23.
3
Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
J Manag Care Spec Pharm. 2023 Nov;29(11):1205-1218. doi: 10.18553/jmcp.2023.23031. Epub 2023 Sep 30.
4
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
Blood Cancer J. 2023 Jul 25;13(1):112. doi: 10.1038/s41408-023-00882-y.
5
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Blood. 2021 Jul 1;137(26):3616-3628. doi: 10.1182/blood.2020008787.
6
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.
Blood Cancer J. 2021 Feb 18;11(2):40. doi: 10.1038/s41408-021-00432-4.
7
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Blood. 2020 Nov 26;136(22):2513-2523. doi: 10.1182/blood.2020007522.
8
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.
9
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
J Clin Oncol. 2015 Oct 20;33(30):3459-66. doi: 10.1200/JCO.2014.60.2466. Epub 2015 Aug 17.
10
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
Am J Hematol. 2015 Apr;90(4):314-9. doi: 10.1002/ajh.23933. Epub 2015 Feb 27.
Zotero 插件